A Multicenter Trial of a Topical Medication for Papulopustular Rosacea Applied Twice Daily Versus Once Daily
Information source: Bayer
ClinicalTrials.gov processed this data on August 20, 2015 Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Papulopustular Rosacea
Intervention: azelaic acid 15% gel (Drug); azelaic acid 15% gel (Drug)
Phase: Phase 4
Status: Completed
Sponsored by: Bayer Official(s) and/or principal investigator(s): Bayer Study Director, Study Director, Affiliation: Bayer
Summary
To assess the efficacy and tolerability of azelaic acid 15% gel applied once daily versus
twice daily in the treatment of patients with papulopustular rosacea.
Clinical Details
Official title: A Multicenter, Double-Blind Clinical Trial to Assess the Efficacy and Tolerability of Topical Azelaic Acid 15% Gel Once Daily Compared to Topical Azelaic Acid 15% gelTwice Daily in Subjects With Papulopustular Rosacea
Study design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment
Primary outcome: Investigator's global assessment scored on a seven point scale
Secondary outcome: Inflammatory lesion count, erythema, telangiectasia, patient self assessment, patient opinion about therapy
Detailed description:
To test the efficacy and safety of once vs twice daily application of azelaic acid 15% gel
on papulopustular rosacea
Eligibility
Minimum age: 18 Years.
Maximum age: N/A.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- Papulopustular facial rosacea; minimum of 10, maximum of 50 inflamed papules and/or
pustules
Exclusion Criteria:
- Mild or severe rosacea
- Rosacea with marked ocular manifestations
- Presence of dermatoses that could interfere with the rosacea diagnosis or evaluation
of the study course
- Wash out period required for patients treated prior to study with topical retinoids,
oral antibiotics, topical antibiotics, systemic and topical corticosteroids, topical
imidazole, laser surgery for telangiectasia
- History of hypersensitivity to propylene glycol
Locations and Contacts
Intendis GmbH, Berlin, Germany
Additional Information
Click here and search for drug information provided by the FDA. Click here and search for information on any recalls, market or product safety alerts by the FDA which might have occurred with this product.
Starting date: January 2007
Last updated: February 20, 2014
|